[Federal Register Volume 61, Number 158 (Wednesday, August 14, 1996)]
[Notices]
[Pages 42256-42257]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 96-20703]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[INFO-96-22]
Proposed Data Collections Submitted for Public Comment and
Recommendations
In compliance with the requirement of Section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995 for opportunity for public comment on
proposed data collection projects, the Centers for Disease Control and
Prevention (CDC) will publish periodic summaries of proposed projects.
To request more information on the proposed projects or to obtain a
copy of the data collection plans and instruments, call the CDC Reports
Clearance Officer on (404) 639-7090.
Comments are invited on: (a) Whether the proposed collection of
information is necessary for the proper performance of the functions of
the agency, including whether the information shall have practical
utility; (b) the accuracy of the agency's estimate of the burden of the
proposed collection of information; (c) ways to enhance the quality,
utility, and clarity of the information to be collected; and (d) ways
to minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques for other
forms of information technology. Send comments to Wilma Johnson, CDC
Reports Clearance Officer, 1600 Clifton Road, MS-D24, Atlanta, GA
30333. Written comments should be received within 60 days of this
notice.
Proposed Projects
1. Surveillance and Evaluation of Blood Donors Positive for Human
Immunodeficiency Virus (HIV) Antibody or HIV Antigen (0920-0329). In
1987, the President directed the Department of Health and Human
Services (DHHS) to determine the nationwide incidence of, to predict
the future of, and to determine the extent to which human
immunodeficiency virus (HIV) is present in various segments of our
population. In response, CDC formed an epidemiologic team to summarize
existing information. An extensive review of published and unpublished
data led to the conclusion that even though there is information
suggesting a very large number of Americans were infected, there was no
substitute for carefully and scientifically obtained incidence and
prevalence data. The need to monitor HIV seroprevalence existed on the
national and at the state and local levels for public health
management: targeting and evaluating prevention programs, planning
future health care needs and determining health policy.
On a national basis, HIV seroprevalence projects in 1987 consisted
of monitoring the HIV status of: Civilian applicants for military
service; blood donors, including follow-up risk factor evaluation in
seropositives; and Job Corps entrants. HIV prevalence was studied in
settings of special public health interest including selected colleges
and prisons, among health care workers in hospital emergency rooms and
among Native Americans and homeless persons. Other national data
sources were examined, such as cohort studies of groups at risk,
including homosexual and bisexual men and IV drug users, providing
information on knowledge of AIDS and risk behaviors, changes in
behavior, and incidence of HIV infection.
In 1987, OMB approved the ``Family of HIV Seroprevalence Surveys''
(0920-0232). These surveys included seven seroprevalence surveys which
involved interaction with individuals (non-blinded surveys). One of
these surveys was the surveillance and evaluation of blood donors
positive for Human Immunodeficiency Virus (HIV) Antibody.
In 1993, OMB again approved for 3 years the surveillance and
evaluation of blood donors who test positive for Human Immunodeficiency
Virus (HIV) Antibody and their needle-sharing and sexual partners
(0920-0329). This request is for an additional 3-year approval. The
total cost to respondents is estimated at $3,784.
[[Page 42257]]
------------------------------------------------------------------------
Average
No. of burden/ Total
Respondents No. of responses/ response burden
respondents respondent (in (in
hrs.) hrs.)
------------------------------------------------------------------------
Blood donors (interviews)... 160 1 1.0 160
Blood donors (refuse
interview)................. 120 1 0.1 12
-------------------------------------------
Total................. ........... .......... ........ 172
--------------
------------------------------------------------------------------------
Dated: August 8, 1996.
Wilma G. Johnson,
Acting Associate Director for Policy Planning and Evaluation, Centers
for Disease Control and Prevention (CDC).
[FR Doc. 96-20703 Filed 8-13-96; 8:45 am]
BILLING CODE 4163-18-P
